CA3166887A1 - Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis - Google Patents

Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis Download PDF

Info

Publication number
CA3166887A1
CA3166887A1 CA3166887A CA3166887A CA3166887A1 CA 3166887 A1 CA3166887 A1 CA 3166887A1 CA 3166887 A CA3166887 A CA 3166887A CA 3166887 A CA3166887 A CA 3166887A CA 3166887 A1 CA3166887 A1 CA 3166887A1
Authority
CA
Canada
Prior art keywords
human
treatment
subject
tregs
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166887A
Other languages
English (en)
French (fr)
Inventor
Gilbert BENSIMON
Peter Nigel LEIGH
Timothy TREE
Cecilia Garlanda
Massimo LOCATI
Janine KIRBY
Pamela Shaw
Andrea MALASPINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Centre Hospitalier Universitaire de Nimes, University of Sheffield, Kings College London, Queen Mary University of London, University of Sussex, Humanitas Mirasole SpA filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of CA3166887A1 publication Critical patent/CA3166887A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3166887A 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis Pending CA3166887A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305241.0 2020-03-06
EP20305241 2020-03-06
PCT/EP2021/055570 WO2021176044A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CA3166887A1 true CA3166887A1 (en) 2021-09-10

Family

ID=71083549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166887A Pending CA3166887A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Country Status (8)

Country Link
US (2) US20230090069A1 (https=)
EP (2) EP4647123A3 (https=)
JP (1) JP7840267B2 (https=)
AU (1) AU2021230103A1 (https=)
CA (1) CA3166887A1 (https=)
ES (1) ES3041723T3 (https=)
TW (1) TWI894224B (https=)
WO (1) WO2021176044A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Also Published As

Publication number Publication date
AU2021230103A1 (en) 2022-09-22
EP4114440C0 (en) 2025-06-25
US20230090069A1 (en) 2023-03-23
JP7840267B2 (ja) 2026-04-03
EP4114440B1 (en) 2025-06-25
TW202146041A (zh) 2021-12-16
EP4647123A3 (en) 2025-12-24
JP2023516774A (ja) 2023-04-20
US20240335510A1 (en) 2024-10-10
EP4647123A2 (en) 2025-11-12
ES3041723T3 (en) 2025-11-14
WO2021176044A1 (en) 2021-09-10
EP4114440A1 (en) 2023-01-11
TWI894224B (zh) 2025-08-21

Similar Documents

Publication Publication Date Title
DK2683395T3 (en) USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
Damoiseaux The IL-2–IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor
US20240335510A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
JP6416855B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
Kluger et al. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet’s syndrome
Topping et al. The effects of intrathecal rituximab on biomarkers in multiple sclerosis
Zhou et al. Induced regulatory T cells suppress Tc1 cells through TGF-β signaling to ameliorate STZ-induced type 1 diabetes mellitus
US20120252896A1 (en) Methods and compositions for modulation of t-cells via the kynurenine pathway
McBride et al. Triggers, timescales, and treatments for cytokine-mediated tissue damage
Czarnecka et al. Palmoplantar pustulosis: Factors causing and influencing the course of the disease
Correale et al. Mitoxantrone as rescue therapy in worsening relapsing–remitting MS patients receiving IFN-β
Bekkat et al. Upregulation of IL4‐induced gene 1 enzyme by B2 cells during melanoma progression impairs their antitumor properties
Yu et al. Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia
Zhao et al. Effects of recombinant human granulocyte colony-stimulating factor on central and peripheral T lymphocyte reconstitution after sublethal irradiation in mice
Criado et al. The OX40-OX40L Co-stimulatory pathway in dermatology: emerging frontiers for therapeutic approaches
Vorozheikina et al. Overview of adverse events associated with anti-CD19 chimeric antigen receptor T-cell therapy
Song et al. ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy
Topping et al. sclerosis, Multiple Sclerosis and Related Disorders
Nomura et al. Dynamic role of cell-derived microparticles in hematopoietic stem cell transplantation

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250225

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250225

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260302

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260302